Italia markets close in 43 minutes

AstraZeneca PLC (AZN.ST)

Stockholm - Stockholm Prezzo in tempo reale. Valuta in SEK.
Aggiungi a watchlist
1.391,50+10,00 (+0,72%)
Al 04:47PM CEST. Mercato aperto.

AstraZeneca PLC

1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
44 20 3749 5000
https://www.astrazeneca.com

Settore/iHealthcare
SettoreDrug Manufacturers—General
Impiegati a tempo pieno83.100

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Pascal Soriot D.V.M., M.B.A.CEO & Exec. Director5,76MN/D1959
Dr. Aradhana Sarin M.D.CFO & Exec. Director4,25MN/D1975
Mr. Marc DunoyerCEO of Alexion & Chief Strategy Officer2,01MN/D1952
Ms. Pam P. ChengEVP of Operations & Information Technology and Member of External Sustainability Advisory BoardN/DN/D1971
Mr. Chris SheldonHead of Investor RelationsN/DN/DN/D
Mr. Jeffrey PottChief HR Officer, Gen. Counsel & Member of External Sustainability Advisory BoardN/DN/DN/D
Ms. Katarina AgeborgEVP of Sustainability, Chief Compliance Officer & Member of External Sustainability Advisory BoardN/DN/DN/D
Gonzalo VinaHead of Global Media RelationsN/DN/DN/D
Dr. Menelas Pangalos Ph.D.EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory BoardN/DN/D1967
Dr. Ruud Dobber Ph.D.Exec. Vice-Pres of BioPharmaceuticals Bus. UnitN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in SEK.

Descrizione

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Governance aziendale

L'ISS Governance QualityScore di AstraZeneca PLC al 31 luglio 2022 è 7. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 8; diritti degli azionisti: 1; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.